Comments
Finoso Pharma Pvt Ltd and the US-based Criti Tech Inc have formed a joint venture — Finotech Pharma.
The 50-50 joint venture would work on providing advanced technology for designing extremely small particles required in drug-making.
“Our experience in dossier-filing for the last three years and Criti Tech expertise in technology will provide strategic opportunity for both parties, Dr K. Kumar, Managing Director, Finoso Pharma, said.
Three key customers were already identified for Fenotech and it would scout for more customers in the domestic and foreign markets, he added.
The Hyderabad-based Finoso, which had a turnover of about Rs 5 crore last year, has contributed its existing facility and 30 employees to the joint venture.
Dr David Johnston, Chief Executive Officer, Criti Tech, said the investment in the joint venture could be around one to two million dollars.
The therapeutic areas to be focussed by Finotech Pharma would be oncology and lung diseases, among others.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.